Supernus Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-29.02	-38.55	73.87	1.32	60.71	53.42
Depreciation & Amortization	97.31	91.56	80.41	84.86	85.54	32.6
Stock-Based Compensation	33.46	33.05	27.76	26.76	17.57	17.91
Other Adjustments	40.83	36.43	-8.03	7.29	-24.85	19.63
Change in Receivables	-13.12	-22.3	2.08	18.77	-16.37	3.87
Changes in Inventories	-12.34	-7.5	15.81	6.11	-17.86	-14.58
Changes in Accrued Expenses	19.59	-7.61	14.43	2.61	18.94	4.5
Changes in Other Operating Activities	-61.44	-37.75	-34.37	-36.62	-6.86	9.78
Operating Cash Flow	83.26	47.33	171.95	111.09	116.83	127.13
Operating Cash Flow Growth	-49.28%	-72.47%	54.79%	-4.91%	-8.10%	-8.14%
Capital Expenditures	-1.01	-1.34	-0.73	-0.55	-0.41	-2.05
Purchases of Investments	-435.82	-475.94	-688.01	-101.62	-406.99	-311.57
Proceeds from Sale of Investments	677.5	774.48	498.87	370.9	190.74	530.51
Payments for Business Acquisitions	-	-293.09	-	-	-	-311.69
Other Investing Activities	-	-	-	-	-	12.89
Investing Cash Flow	-52.43	4.11	-189.87	268.73	-216.66	-81.91
Short-Term Debt Issued	-	-	-	93	-	-
Short-Term Debt Repaid	-	-	-	-93	-	-
Long-Term Debt Issued	-	-	-	-	-	0.8
Long-Term Debt Repaid	-	-	-	-402.5	-	-138.32
Net Long-Term Debt Issued (Repaid)	-	-	-	-402.5	-	-137.52
Issuance of Common Stock	49.24	37.62	14.91	6.61	12.42	7.1
Net Common Stock Issued (Repurchased)	49.24	37.62	14.91	6.61	12.42	7.1
Other Financing Activities	-9.6	-28.49	-2.72	-1.99	-22.9	-
Financing Cash Flow	39.64	9.13	12.19	-397.88	-10.48	-130.42
Net Cash Flow	70.47	60.57	-5.72	-18.07	-110.31	-85.21
Free Cash Flow	82.25	45.99	171.23	110.53	116.41	125.08
Free Cash Flow Growth	78.82%	-73.14%	54.91%	-5.05%	-6.93%	-7.15%
FCF Margin	10.59%	6.40%	25.87%	18.19%	17.45%	21.57%
Free Cash Flow Per Share	1.44	0.81	3.06	1.99	1.89	2.30
Levered Free Cash Flow	13.1	-1.18	149.42	-344.78	140.07	-53.84
Unlevered Free Cash Flow	6.48	-11.6	137.19	53.9	125.45	93.06

SEC Filings: 10-K · 10-Q